title: [A modern therapeutic strategy in Ph-positive chronic myeloleukemia].
abstract: The aim of this paper was to show the validity of programmed treatment of chronic myeloid leukemia (CML) patients regarding the risk group. In a group of low CML risk monochemotherapy (myelosan or hydroxyurea) was applied. In a group of moderate or high CML risk cytostatic therapy was performed in two variants: as monotherapy and polychemotherapy. Of 112 patients with CML, 50 received cytostatics plus long-term course of interferon-alpha. The combined treatment was well tolerated.
authors.forename: N D
authors.initials: ND
authors.lastname: Khoroshko
authors.forename: A G
authors.initials: AG
authors.lastname: Turkina
authors.forename: V S
authors.initials: VS
authors.lastname: Zhuravlev
authors.forename: M A
authors.initials: MA
authors.lastname: Sokolova
authors.forename: I N
authors.initials: IN
authors.lastname: Mikhaĭlova
authors.forename: A V
authors.initials: AV
authors.lastname: Zakharova
authors.forename: E V
authors.initials: EV
authors.lastname: Domracheva
authors.forename: E A
authors.initials: EA
authors.lastname: Semenova
mesh_terms: D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002066:Busulfan / Q000008:administration & dosage; D002908:Chronic Disease; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D007370:Interferon Type I / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction; D012307:Risk Factors; D013997:Time Factors
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007370:Interferon Type I; D011994:Recombinant Proteins; D002066:Busulfan; D006918:Hydroxyurea